HEMO +
Oral medication to treat hemophila
- Home page /
- Our innovative offers /
- Therapeutic
Competitive advantages
- Oral administration
- Better quality of life for patients
- Low cost
It is a non-invasive, inexpensive treatment that presents little risk of generating antibodies and therefore resistance.
Market opportunities
- Hemophilia
- Molecule repositioning
- Oral administration
Development level
Following a screening of existing molecules, a hit has been identified for the coagulation of hemophilia plasma and an optimization work by structural analogy is in progress.
TRL3
Search for partnerships
Maturation (via SATT Linksium)
Intellectual property
1 patent (WO/2022/018256)
Researcher / Laboratory
Aline Thomas / DPM
Presentation
Hemophilia is a rare disease due to a deficiency of clotting factor FVIII or FIX depending on whether it is hemophilia A or B. Usually, patients are treated with injection replacement therapy, which generates resistance in approximately 30% of patients.
We offer the first orally administrable chemical drug based on a repositioning approach.
Uses
This treatment would target all types of hemophilia.
Contacts
7 Allée Palestine
38610 Gières
Tél : +33 (0)4 56 52 04 30
E-mail : contact@floralis.fr
